The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cheng, I used to be invested in Avacta. I did say almost entirely obviously they along with the other companies still have their primary focuses it would be catasatrophic if they didn't. In turn Sareum have more than just a potential focus on covid19 and rispiratory conditions.
Fair shout Utah, we all have different views and that must be respected.
No ahfam you can't speak for all lth,currently 2 deals.sierra I doubt they had much say in it but that has currently imploded the second is a real shot in dark with an un named Chinese pharma.so I would so they need to work harder to convince us
Delusional.The coronavirus route is just Tim jumping on the bandwagon trying to get a bit more mileage out of all these amazing componds we e have got(where are the deals?,).Just delaying tactics so he can squeeze a fewmore poster/conference presentations out of it before he retires and leaves everybody high and dry
Brighty, Steve- the real long-term holders know how Sareum operate and trust John and Tim to bring the best deal(s) to the table. We expected there to be a deal to be done but in my opinion covid changed the landscape- we have seen companies like Avacta, Hemo and Novacyte transform to cater for almost entirely covid19, however, Sareum have 2 tyk2's one for Cancer and the other for auto-immune which are massive markets as it is- it just so happens by a stroke of luck the auto-immune is also able to cater not only for Covid19 but for the whole respiratory market as we have seen from the presentations done by Sareum. As I was saying the deal I believed would have happened and that's why Thoth mentioned 6months but with Covid19 the value of tyk2 auto-immune as risen exponentially to a point that Governments let alone large Pharma are interested in anything and everything which can cater for respiratory illnesses like covid19 which will be with the world for at least 18-36 months if not longer. As mentioned by Basser and many others before once Sareum do make an application(s) it will be fast-tracked in more ways than one. So as always just a little patience required and we all know nothing goes up in a straight line, however, once news drops we all know how Sareum's share-price can move- the whole world has been affected by covid19 and many business have and will disappear but Sareum are very much in the mix a bit slow but sometimes the best things come to those who are patient. Lots of news to come, science is still good, nothing has been dumped and even Aurora which was shelved has been given a new lease of life- so plenty to look forward to- Many happy returns chaps.
Well said Steve. The difference now is there is a mood of "We've had enough" from many of the long term holders. Share holders want to be updated regularly. The silence is not going to be acceptable for too much longer. What have Tim, John, Steven, Clive and Michael been up to for the last year? Brighty
Here we go again, how many more months before we get any news. Thoth2 said 6 months this time last year.
I'm tried of seeing people put months here and there.
The lazy bod run the company not you lot.
And where still waiting for company update.
I don’t wish to be an apologist for the Sareum bod (I am critical of their lack of commercial success to date and bemused by their woeful PR / comms skills) but I do feel that the next 3-6 months could be the most decisive in the history of Sareum. There are at least 4 substantial prospects that we should be hearing about:
1. Sierra
2. China
3. Tyk2 Licencing
4. Research Grant
We should know about points 1 & 4 within the next quarter, point 2 within the next 5 months & point 3 could arise at any time. These opportunities could and should – if communicated correctly – be the catalyst for the share price to move north.